orexigen therapeutics inc
(OREX:NASDAQ GS)

Executive Profile*

Background*

Dr. Eckard Weber serves as the Chief Executive Officer and President at Nanothera Corporation and of Abrexa Pharmaceuticals, Inc. Dr. Weber is a Partner at Domain Associates, L.L.C. and joined it in 2001. Dr. Weber joined in that role where he specializes in creating companies around promising new pharmaceutical products. He has over 20 years of drug discovery and development experience and has been a Consultant to biotechnology and pharmaceutical companies. Dr. Weber ... serves as an Interim Chief Executive Officer of Tramoxia Therapeutics. He has been the Founding Chief Executive Officer of various companies including Cytovia, Acea Pharmaceuticals, Novacea, NovaCardia, Novalar Pharmaceuticals, Calixa Therapeutics, Sonexa Therapeutics, Domain Antibacterial Acquisition Corporation, Ascenta Therapeutics, Konova, Ocera, Syndax, Tragara, Tobira, and Tramoxia Therapeutics. Dr. Weber also serves as an Interim Chief Executive Officer of Tragara Pharmaceuticals and Syndax Pharmaceuticals, Nanothera Corporation, Calixa Therapeutics, and Sonexa Therapeutics. He has been the Chief Executive Officer of Novalar Pharmaceuticals, Inc. since January 2001. Dr. Weber has been an Interim Chief Executive Officer of Domain Antibacterial Acquisition Corporation, since April 2002. He was Co-Founder of Orexigen Therapeutics, Inc. and served as its Interim Chief Executive Officer and Interim President from November 2008 to March 2009 and also served as its Executive Chairman from November 2008 to March 31, 2009. From December 2001 to March 2003, he served as an Interim Chief Executive Officer of NovaCardia. From October 2000 to December 2000, Dr. Weber served as a Senior Director of Research at Maxim Pharmaceuticals. From June 2000 to September 2000, he served as a Senior Vice President of Research at Maxim Pharmaceuticals. Dr. Weber served as the Chief Executive Officer of Cytovia, Inc., from January 1998 to May 2000. He was a Senior Vice President of Research and Drug Discovery of Cocensys Inc., from November 1995 to December 1997. Dr. Weber actively manages, on an interim-basis, the companies he found, until permanent, full-time management has been recruited. Dr. Weber has been the Non-Executive Chairman of Orexigen Therapeutics, Inc. since March 2009. He serves as the Chairman of Novacea, Novalar, Ocera, Ascenta, Sonexa Therapeutics, Inc., Syndax Pharmaceuticals, Calixa Therapeutics, Sequel Pharmaceuticals, and Tragara Pharmaceuticals. Dr. Weber served as the Chairman of Peninsula Pharmaceuticals from October 2003 to 2005. Dr. Weber served as the Chairman of Cerexa until 2007. He served as the Chairman of NovaCardia until September of 2007. Dr. Weber is an Observer on the Board of Syndax Pharmaceuticals and a Board member of Adynxx. In addition, he serves as a Director of BioVascular, Tobira Therapeutics, and DiObex. He has been a Director of Peninsula Pharmaceuticals Inc. since October 2002. Dr. Weber serves as Director of Tragara Pharmaceuticals, Inc. and of Renovia and BBB Biotechnologies. He serves as a Director of Nanothera Corporation and of Abrexa Pharmaceuticals, Inc. He served as a Director of Cocensys Inc. since June 1994. He served as a Director of Conforma and Cabrellis. From 1989 until 1995 Dr. Weber was a tenured Professor of Pharmacology at the University of California at Irvine. He is the inventor or co-inventor of over 40 patents and patent applications, and Dr. Weber has published over 130 papers in scientific periodicals. He received a B.S. from Kolping College, Friedrichshafen, Germany in 1974 and an M.D. from the University of Ulm Medical School in Germany in 1979. Dr. Weber pursued his postdoctoral training at the Stanford University Medical School between 1980 and 1982.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
OREX:US	$6.45 USD	-0.03

COMPETITOR COMPENSATION